Literature DB >> 28686520

Mindfulness-based interventions for women with breast cancer: an updated systematic review and meta-analysis.

Heidemarie Haller1, María M Winkler2, Petra Klose1, Gustav Dobos1, Sherko Kümmel3, Holger Cramer1.   

Abstract

BACKGROUND: The aim of this meta-analysis was to systematically update the evidence for mindfulness-based stress reduction (MBSR) and mindfulness-based cognitive therapy (MBCT) in women with breast cancer.
MATERIAL AND METHODS: In October 2016, PubMed, Scopus, and Central were searched for randomized controlled trials on MBSR/MBCT in breast cancer patients. The primary outcome was health-related quality of life. Secondary outcomes were fatigue, sleep stress, depression, anxiety, and safety. For each outcome, standardized mean differences (SMD/Hedges' g) and 95% confidence intervals (CI) were calculated. Risk of bias was assessed by the Cochrane risk of bias tool.
RESULTS: The Literature search identified 14 articles on 10 studies that included 1709 participants. The overall risk of bias was unclear, except for risk of low attrition bias and low other bias. Compared to usual care, significant post-intervention effects of MBSR/MBCT were found for health-related quality of life (SMD = .21; 95%CI = [.04-.39]), fatigue (SMD = -.28; 95%CI = [-.43 to -.14]), sleep (SMD = -.23; 95%CI = [-.40 to -.05]), stress (SMD = -.33; 95%CI = [-.61 to -.05]), anxiety (SMD = -.28; 95%CI = [-.39 to -.16]), and depression (SMD = -.34; 95%CI = [-.46 to -.21]). Up to 6 months after baseline effects were significant for: anxiety (SMD = -.28; 95%CI = [-.47 to -.09]) and depression (SMD = -.26; 95%CI = [-.47 to -.04]); and significant for anxiety (SMD = -.21; 95%CI = [-.40 to -.03]) up to 12 months after baseline. Compared to other active interventions, significant effects were only found post-intervention and only for anxiety (SMD = -.45; 95%CI = [-.71 to -.18]) and depression (SMD = -.39; 95%CI = [-.65 to -.14]). However, average effects were all below the threshold of minimal clinically important differences. Effects were robust against potential methodological bias. Adverse events were insufficiently reported.
CONCLUSIONS: This meta-analysis revealed evidence for the short-term effectiveness and safety of mindfulness-based interventions in women with breast cancer. However, their clinical relevance remains unclear. Further research is needed.

Entities:  

Mesh:

Year:  2017        PMID: 28686520     DOI: 10.1080/0284186X.2017.1342862

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  57 in total

1.  Exploring the Relationship between Diarrhea and Fatigue that can occur during Cancer Treatment: Using Structural Equation Modeling.

Authors:  Velda J Gonzalez; Jason Beckstead; Maureen Groer; Susan McMillan; Desiree Ortiz; Sara Marrero; Leorey N Saligan
Journal:  P R Health Sci J       Date:  2019-06       Impact factor: 0.705

2.  A Pilot Mobile-based Mindfulness Intervention for Cancer Patients and their Informal Caregivers.

Authors:  Ai Kubo; Andrea Altschuler; Elaine Kurtovich; Sarah Hendlish; Cecile A Laurent; Tatjana Kolevska; Yan Li; Andrew Avins
Journal:  Mindfulness (N Y)       Date:  2018-03-24

3.  Mind-body medicine use by women diagnosed with breast cancer: results of a nationally representative survey.

Authors:  Petra Voiß; Melanie Désirée Höxtermann; Gustav Dobos; Holger Cramer
Journal:  Support Care Cancer       Date:  2019-06-11       Impact factor: 3.603

4.  Mindfulness and Meditative Movement Interventions for Men Living With Cancer: A Meta-analysis.

Authors:  C Graham Ford; Kevin E Vowles; Bruce W Smith; Anita Y Kinney
Journal:  Ann Behav Med       Date:  2020-04-20

5.  Coping Skills Practice and Symptom Change: A Secondary Analysis of a Pilot Telephone Symptom Management Intervention for Lung Cancer Patients and Their Family Caregivers.

Authors:  Joseph G Winger; Kevin L Rand; Nasser Hanna; Shadia I Jalal; Lawrence H Einhorn; Thomas J Birdas; DuyKhanh P Ceppa; Kenneth A Kesler; Victoria L Champion; Catherine E Mosher
Journal:  J Pain Symptom Manage       Date:  2018-01-31       Impact factor: 3.612

6.  Mindfulness-based stress reduction for HIV-associated neurocognitive disorder: Rationale and protocol for a randomized controlled trial in older adults.

Authors:  Elizabeth L Addington; Shireen Javandel; Victor De Gruttola; Robert Paul; Benedetta Milanini; Beau M Ances; Judith T Moskowitz; Victor Valcour
Journal:  Contemp Clin Trials       Date:  2020-09-15       Impact factor: 2.226

7.  Distress Management, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Michelle B Riba; Kristine A Donovan; Barbara Andersen; IIana Braun; William S Breitbart; Benjamin W Brewer; Luke O Buchmann; Matthew M Clark; Molly Collins; Cheyenne Corbett; Stewart Fleishman; Sofia Garcia; Donna B Greenberg; Rev George F Handzo; Laura Hoofring; Chao-Hui Huang; Robin Lally; Sara Martin; Lisa McGuffey; William Mitchell; Laura J Morrison; Megan Pailler; Oxana Palesh; Francine Parnes; Janice P Pazar; Laurel Ralston; Jaroslava Salman; Moreen M Shannon-Dudley; Alan D Valentine; Nicole R McMillian; Susan D Darlow
Journal:  J Natl Compr Canc Netw       Date:  2019-10-01       Impact factor: 11.908

8.  Using SMART design to improve symptom management among cancer patients: A study protocol.

Authors:  Alla Sikorskii; Gwen Wyatt; Rebecca Lehto; David Victorson; Terry Badger; Thaddeus Pace
Journal:  Res Nurs Health       Date:  2017-11-11       Impact factor: 2.228

Review 9.  The relationship between acceptance of cancer and distress: A meta-analytic review.

Authors:  Ekin Secinti; Danielle B Tometich; Shelley A Johns; Catherine E Mosher
Journal:  Clin Psychol Rev       Date:  2019-05-03

10.  What do cancer survivors and their health care providers want from a healthy living program? Results from the first round of a co-design project.

Authors:  Ashley R Grant; Bogda Koczwara; Julia N Morris; Elizabeth Eakin; Camille E Short; Lisa Beatty
Journal:  Support Care Cancer       Date:  2021-02-05       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.